Gyre Therapeutics Inc. (GYRE)
12.61
0.47 (3.87%)
At close: Feb 20, 2025, 3:59 PM
12.56
-0.40%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 12.33 |
| Market Cap | 1.08B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.04 |
| PE Ratio (ttm) | -12.12 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 13.05 |
| Volume | 37,204 |
| Avg. Volume (20D) | 105,796 |
| Open | 12.20 |
| Previous Close | 12.14 |
| Day's Range | 12.18 - 12.65 |
| 52-Week Range | 8.26 - 26.37 |
| Beta | undefined |
About GYRE
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 12, 2006
Employees 593
Stock Exchange NASDAQ
Ticker Symbol GYRE
Website https://www.gyretx.com
3 months ago
-9.56%
Gyre Therapeutics shares are trading lower after t...
Unlock content with
Pro Subscription
7 months ago
Gyre Therapeutics shares are trading higher after the company announced that China's NMPA approved Avatrombopag Maleate tablets for the treatment of CLD-associated thrombocytopenia.
